Original Article Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors

  • Endocrinol Metab
  • Wonjin Kim
  • Yoonjung Chung
  • Se Hwa Kim
  • Sehee Park
  • Jae Hyun Bae
  • Gyuri Kim
  • Su Jin Lee
  • Jo Eun Kim
  • Byeong-woo Park
  • Sung-kil Lim
  • Yumie Rhee
Publication date
August 2016

Abstract

Background: Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which inhibits bone formation. Aromatase inhibitors (AIs), which reduce the conversion of steroids to estrogen, are used to treat endocrine-responsive breast cancer. As AIs lower estrogen levels, they increase bone turnover and lower bone mass. We analyzed changes in serum sclerostin levels in Korean women with breast cancer who were treated with an AI. Methods: We included postmenopausal women with endocrine-responsive breast cancer (n=90; mean age, 57.7 years) treated with an AI, and compared them to healthy premenopausal women (n=36; mean age, 28.0 years). The subjects were randomly as-signed to take either 5 mg alendronate with 0.5 µg calcitrio...

Extracted data

We use cookies to provide a better user experience.